Profile data is unavailable for this security.
About the company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.
- Revenue in USD (TTM)2.09bn
- Net income in USD-332.26m
- Incorporated2003
- Employees2.10k
- LocationAlnylam Pharmaceuticals Inc675 W Kendall StCAMBRIDGE 02142-1168United StatesUSA
- Phone+1 (617) 551-8200
- Fax+1 (617) 551-8101
- Websitehttps://www.alnylam.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viatris Inc | 15.05bn | -883.30m | 15.96bn | 38.00k | -- | 0.8063 | 8.36 | 1.06 | -0.7389 | -0.7389 | 12.54 | 16.58 | 0.3219 | 2.23 | 4.94 | 396,013.20 | -1.89 | 0.0887 | -2.23 | 0.1061 | 42.49 | 40.29 | -5.87 | 0.2891 | 0.9615 | 2.37 | 0.443 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
| Biogen Inc | 9.61bn | 1.62bn | 23.01bn | 7.57k | 14.27 | 1.40 | 10.16 | 2.39 | 11.07 | 11.07 | 65.83 | 112.90 | 0.34 | 0.8604 | 4.58 | 1,269,155.00 | 5.71 | 12.53 | 7.01 | 14.83 | 75.59 | 83.04 | 16.80 | 26.93 | 0.8039 | 4.89 | 0.2778 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
| Alnylam Pharmaceuticals, Inc. | 2.09bn | -332.26m | 31.59bn | 2.10k | -- | 975.21 | -- | 15.08 | -2.62 | -2.62 | 16.52 | 0.2511 | 0.5208 | 3.57 | 8.41 | 997,521.40 | -8.26 | -26.56 | -11.31 | -32.77 | 85.37 | 83.66 | -15.86 | -94.26 | 2.69 | -1.36 | 0.9694 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 16.51m | 12.86% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 13.83m | 10.77% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 12.32m | 9.60% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 6.60m | 5.14% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2024 | 5.24m | 4.09% |
| Baillie Gifford & Co.as of 30 Sep 2024 | 4.89m | 3.81% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 4.83m | 3.76% |
| Capital Research & Management Co. (International Investors)as of 30 Sep 2024 | 3.97m | 3.09% |
| Dodge & Coxas of 30 Sep 2024 | 3.62m | 2.82% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 3.47m | 2.70% |
